Catalog No.: PC-20708Not For Human Use, Lab Use Only.
HSN608 (HSN 608) is a potent inhibitor of RET solvent-front mutants, inhibits RET G810 solvent-front mutants and the V804M gatekeeper mutant with IC50 of <50 nM in cell culture, inhibits ABL1(T315I) with IC50 of 40.7 nM.
HSN608 (HSN 608) is a potent inhibitor of RET solvent-front mutants, inhibits RET G810 solvent-front mutants and the V804M gatekeeper mutant with IC50 of <50 nM in cell culture, inhibits ABL1(T315I) with IC50 of 40.7 nM.
HSN608 inhibits selpercatinib/pralsetinib-resistant RET G810 mutants.
HSN608 inhibits ABL1 and ABL1(T315I) activities in KCL22 and KCL22-IR cell lines.
Oral administration of HSN608 at a well-tolerated dose (30 mg/kg) gave plasma level > 30x the IC50s of inhibiting all G810 mutants in cell culture.
HSN608 significantly suppressed and caused regression of the selpercatinib-resistant tumors of cell-derived xenograft tumors driven by KIF5B-RET (G810C).
